| Literature DB >> 35840967 |
Karin Boson1,2, Mats Anderberg3, Johan Melander Hagborg4, Peter Wennberg5,6, Mikael Dahlberg7.
Abstract
BACKGROUND: Although several studies have found a high incidence of coexisting mental health problems among adolescents with substance use problems, follow-up studies addressing how these conditions change over time are rare. The study will describe and analyze indications of mental health problems and how various risk factors predict outcomes 1 year after initial treatment contact. In addition, gender-specific risk factors are explored.Entities:
Keywords: Adolescents; Gender differences; Mental health problems; Outpatient treatment; Risk factors; Substance use problems
Mesh:
Year: 2022 PMID: 35840967 PMCID: PMC9284845 DOI: 10.1186/s13011-022-00482-2
Source DB: PubMed Journal: Subst Abuse Treat Prev Policy ISSN: 1747-597X
Indications of mental health problems at one-year follow-up. The data are presented as percentages. Gender differences were tested using a Chi2 test (ns = not significant)
| Total (%) | Girls (%) | Boys (%) | Cramér’s V | |
|---|---|---|---|---|
| 42 | 55 | 37 | 0.168*** | |
| Outpatient treatment, psychiatry | 30 | 41 | 25 | 0.164*** |
| In-patient treatment, psychiatry | 6 | 8 | 6 | ns |
| Medical treatment, mental illness | 31 | 42 | 26 | 0.154*** |
*p < 0.05
**p < 0.01
***padj < 0.05
Bivariate associations and logistic regression analyses of risk factors regarding indications of mental health problems. Odds ratios and confidence intervals are presented (n = 455)
| Bivariate associations | Model 1 | Model 2 | |
|---|---|---|---|
| Full Model | |||
| OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| 1. | 1.18 (0.73–1.90) | 0.90 (0.54–1.49) | 1.03 (0.59–1.78) |
| 2. | 1.42 (0.91–2.20) | 1.16 (0.72–1.87) | 1.13 (0.70–1.83) |
| 3. | 1.68 (1.06–2.66)* | 1.65 (1.01–2.68)* | 1.73 (1.053–2.85)* |
| 4. | 1.22 (0.83–1.78) | 0.94 (0.61–1.45) | 0.98 (0.63–1.52) |
| 5. | 1.01 (0.65–1.58) | 0.90 (0.56–1.46) | 0.81 (0.50–1.32) |
| 6. | 0.93 (0.59–1.49) | 0.87 (0.54–1.43) | 0.99 (0.60–1.65) |
| 7. | 1.36 (0.94–2.04) | 1.16 (0.75–1.79) | 1.13 (0.72–1.78) |
| 8. | 2.51 (1.68–3.74)*** | 2.51 (1.61–3.91)*** | 2.55 (1.60–4.08)*** |
| 9. | 1.27 (0.81–1.98) | 0.95 (0.59–1.55) | 0.95 (0.58–1.57) |
| 10. | 1.16 (0.79–1.72) | 0.89 (0.57–1.38) | 0.80 (0.51–1.27) |
*p < 0.05
**p < 0.01
***padj < 0.05
Note. Model 1 includes risk factors 1–10 and Model 2 risk factors 1–10 but also includes age, gender, and primary drug use frequency at intake
Odds ratios and confidence intervals for the association between adolescent cumulative risk and indications of mental health problems at one-year follow-up (n = 455)
| Model 3 | Model 4 | |
|---|---|---|
| Full Model | ||
| OR (95% CI) | OR (95% CI) | |
| 0–2 risk factors (31%), reference | 1 | 1 |
| 3–5 risk factors (49%) | 1.32 (0.85–2.05) | 1.26 (0.80–1.99) |
| 6–10 risk factors (21%) | 2.48 (1.45–4.24)** | 2.33 (1.31–4.15)** |
**p < 0.01
***padj < 0.05
Note. Model 4 includes the level of cumulative risk as well as age, gender, and primary drug use frequency at intake
Prevalence of mental illness symptoms at treatment initiation. The data are presented as percentages. Gender differences were tested using a Chi2 test (ns = not significant)
| Mental illness symptoms | Total | Girls | Boys | Cramer’s V |
|---|---|---|---|---|
| 53 | 62 | 49 | 0.113* | |
| 34 | 42 | 30 | 0.110* | |
| 51 | 70 | 43 | 0.248*** | |
| 60 | 69 | 56 | 0.124* | |
| 23 | 24 | 22 | ns | |
| 8 | 13 | 7 | 0.097* | |
| 6 | 9 | 5 | ns | |
| 23 | 25 | 22 | ns | |
| 9 | 13 | 7 | 0.106* | |
| 7 | 13 | 4 | 0.156** |
*p < 0.05
**p < 0.01
***padj < 0.05
Bivariate associations and logistic regression analyses of mental illness symptoms at treatment start regarding indications of mental health problems at one-year follow-up. Odds ratios and confidence intervals are presented (n = 455)
| Bivariate associations | Model 5 | Model 6 | |
|---|---|---|---|
| Full Model | |||
| Mental illness symptoms | OR (95% CI) | OR (95% CI) | OR (95% CI) |
| 2.11 (1.44–3.10)*** | 1.28 (0.81–2.02) | 1.38 (0.86–2.20) | |
| 2.61 (1.74–3.90)*** | 1.66 (1.01–2.75)* | 1.85 (1.10–3.12)* | |
| 2.50 (1.70–3.67)*** | 1.46 (0.89–2.39) | 1.38 (0.83–2.31) | |
| 1.86 (1.26–2.76)** | 1.38 (0.87–2.17) | 1.39 (0.87–2.20) | |
| 1.31 (0.84–2.05) | 0.68 (0.40–1.15) | 0.67 (0.39–1.15) | |
| 4.31 (2.03–9.14)*** | 3.21 (1.32–7.81)* | 3.59 (1.45–8.92)** | |
| 3.66 (1.57–8.56)** | 1.76 (0.70–4.46) | 1.75 (0.68–4.52) | |
| 2.32 (1.18–4.58)* | 1.43 (0.68–3.02) | 1.46 (0.68–3.16) | |
| 2.38 (1.13–5.03)* | 0.98 (0.41–2.31) | 0.92 (0.38–2.21) |
*p < 0.05
**p < 0.01
***padj < 0.05
Note. Model 5 includes all mental illness symptoms and Model 6 mental illness symptoms as well as age, gender, and primary drug use frequency at intake